DE3910760C2 - - Google Patents
Info
- Publication number
- DE3910760C2 DE3910760C2 DE3910760A DE3910760A DE3910760C2 DE 3910760 C2 DE3910760 C2 DE 3910760C2 DE 3910760 A DE3910760 A DE 3910760A DE 3910760 A DE3910760 A DE 3910760A DE 3910760 C2 DE3910760 C2 DE 3910760C2
- Authority
- DE
- Germany
- Prior art keywords
- gamma
- linolenic acid
- phospholipids
- glycolipids
- amides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 206010003645 Atopy Diseases 0.000 claims abstract description 8
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims abstract description 7
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims abstract description 7
- 229960002733 gamolenic acid Drugs 0.000 claims abstract description 7
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 7
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 6
- 150000001408 amides Chemical class 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims abstract description 5
- 230000001154 acute effect Effects 0.000 claims abstract description 5
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 230000000699 topical effect Effects 0.000 claims abstract description 3
- 150000003165 prostaglandin E1 derivatives Chemical class 0.000 claims description 6
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 claims 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 abstract description 5
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- IUKXMNDGTWTNTP-RHDCIPCHSA-N 15-HETrE Chemical compound CCCCCC(O)\C=C\C=C/C\C=C/CCCCCCC(O)=O IUKXMNDGTWTNTP-RHDCIPCHSA-N 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 235000008524 evening primrose extract Nutrition 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 235000004496 Oenothera biennis Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 241000235575 Mortierella Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 240000008916 Oenothera biennis Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940045761 evening primrose extract Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pediatric Medicine (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3910760A DE3910760A1 (de) | 1989-04-04 | 1989-04-04 | Neue verwendung bekannter substanzen sowie verfahren zur herstellung von geeigneten praeparaten |
| AT90105854T ATE157541T1 (de) | 1989-04-04 | 1990-03-28 | Pge1 und derivate für mukosale oder dermale anwendung |
| EP90105854A EP0399175B1 (en) | 1989-04-04 | 1990-03-28 | PGE1 and derivatives for dermal or mucosal application |
| DE69031360T DE69031360T2 (de) | 1989-04-04 | 1990-03-28 | PGE1 und Derivate für mukosale oder dermale Anwendung |
| CA002013809A CA2013809C (en) | 1989-04-04 | 1990-04-04 | Agent for the prophylaxis of atopy and methods for preparing and using same |
| US08/420,334 US5591446A (en) | 1989-04-04 | 1995-04-11 | Methods and agents for the prophylaxis of atopy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3910760A DE3910760A1 (de) | 1989-04-04 | 1989-04-04 | Neue verwendung bekannter substanzen sowie verfahren zur herstellung von geeigneten praeparaten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3910760A1 DE3910760A1 (de) | 1990-10-11 |
| DE3910760C2 true DE3910760C2 (enExample) | 1992-01-02 |
Family
ID=6377750
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3910760A Granted DE3910760A1 (de) | 1989-04-04 | 1989-04-04 | Neue verwendung bekannter substanzen sowie verfahren zur herstellung von geeigneten praeparaten |
| DE69031360T Expired - Fee Related DE69031360T2 (de) | 1989-04-04 | 1990-03-28 | PGE1 und Derivate für mukosale oder dermale Anwendung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69031360T Expired - Fee Related DE69031360T2 (de) | 1989-04-04 | 1990-03-28 | PGE1 und Derivate für mukosale oder dermale Anwendung |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0399175B1 (enExample) |
| AT (1) | ATE157541T1 (enExample) |
| DE (2) | DE3910760A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252602A (en) * | 1991-10-11 | 1993-10-12 | Rafeul Alam | Effects of misoprostol on allergic responses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4009282A (en) * | 1973-12-17 | 1977-02-22 | The Regents Of The University Of Michigan | Treatment of proliferating skin diseases with prostaglandins |
| GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
| DE69025787T2 (de) * | 1989-04-04 | 1996-10-31 | Beiersdorf Ag | Mittel zur Atopieprophylaxe |
-
1989
- 1989-04-04 DE DE3910760A patent/DE3910760A1/de active Granted
-
1990
- 1990-03-28 EP EP90105854A patent/EP0399175B1/en not_active Expired - Lifetime
- 1990-03-28 AT AT90105854T patent/ATE157541T1/de not_active IP Right Cessation
- 1990-03-28 DE DE69031360T patent/DE69031360T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69031360T2 (de) | 1998-04-02 |
| DE3910760A1 (de) | 1990-10-11 |
| DE69031360D1 (de) | 1997-10-09 |
| EP0399175B1 (en) | 1997-09-03 |
| ATE157541T1 (de) | 1997-09-15 |
| EP0399175A2 (en) | 1990-11-28 |
| EP0399175A3 (en) | 1992-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68911103T2 (de) | Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis. | |
| DE60000133T2 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
| DE4133694C2 (de) | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen | |
| EP0347056B1 (en) | Essential fatty acid compositions | |
| DE60212786T2 (de) | Verwendung mehrfach ungesättigter Fettsäuren zur primären Prävention kardiovaskulärer Ereignisse | |
| DE69618158T2 (de) | Pharmazeutische Zusammensetzung enthaltend ein Alkanoyl-L-Carnitin in Kombination mit einer polyungesättigten Fettsäure der Omega-3-Serie zur Verhütung und Behandlung von Störungen des Fettstoffwechsels | |
| DE2903558C2 (de) | Verwendung von L-Carnitin | |
| DE69821624T2 (de) | 9-cis-RETINSÄURE FÜR ZELLVERMITTELTE IMMUNKRANKHEITEN | |
| DE69100724T2 (de) | Zusammensetzungen essentieller Fettsäuren und Therapie. | |
| DE69612755T2 (de) | Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen | |
| DE2911670A1 (de) | Arzneimittel zur therapeutischen behandlung von peripheren vaskularen erkrankungen | |
| DE2903579A1 (de) | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel | |
| EP2222292A2 (de) | Neue verwendung von omega-3-fettsäure(n) | |
| EP0456764B1 (de) | Omega-3-fettsäurenhaltige fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung | |
| DE60132008T2 (de) | Cetylmyristat und cetylpalmitat zur behandlung von ekzemen und/oder psoriasis | |
| DE68926115T2 (de) | Verfahren zur behandlung von akne | |
| DE2425988A1 (de) | Medikament zur bekaempfung von erregungsund angstsyndromen | |
| DE69015910T2 (de) | Pharmazeutische Verwendung von Fettsäuren. | |
| DE69317716T2 (de) | Verwendung von Fettsäuren zur Behandlung von abnormalen Verkalkung des Gewebes | |
| DE69025787T2 (de) | Mittel zur Atopieprophylaxe | |
| DE60207442T2 (de) | VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION | |
| DE202004015931U1 (de) | Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung | |
| DE3910760C2 (enExample) | ||
| WO1994005270A1 (de) | Thiol-derivate zur aufrechterhaltung und/oder steigerung der muskelleistung und körperzellmasse | |
| DE60305534T2 (de) | Verwendung von docosahexaensäure als wirkstoff bei der behandlung von lipodystrophie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: DALTEX MEDICAL SCIENCES, INC., FAIRFIELD, N.J., US |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: VON KREISLER, A., DIPL.-CHEM. SELTING, G., DIPL.-ING. WERNER, H., DIPL.-CHEM. DR.RER.NAT. FUES, J.,DIPL.-CHEM. DR.RER.NAT. BOECKMANN GEN. DALLMEYER, G., DIPL.-ING. HILLERINGMANN, J., DIPL.-ING. JOENSSON, H., DIPL.-CHEM. DR.RER.NAT. MEYERS, H., DIPL.-CHEM. DR.RER.NAT., PAT.-ANWAELTE, 5000 KOELN |
|
| 8381 | Inventor (new situation) |
Free format text: MELNIK, BODO, DR.MED., 4830 GUETERSLOH, DE PLEWIG, GERD, PROF. DR.MED., 8000 MUENCHEN, DE |
|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: BEIERSDORF AG, 2000 HAMBURG, DE |
|
| 8339 | Ceased/non-payment of the annual fee |